US4526988A
(en)
*
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
EP0184365B1
(en)
*
|
1984-12-04 |
1993-08-04 |
Eli Lilly And Company |
Improvements in the treatment of tumors in mammals
|
ZA859008B
(en)
*
|
1984-12-04 |
1987-07-29 |
Lilly Co Eli |
The treatment of tumors in mammals
|
CA1295998C
(en)
*
|
1985-07-29 |
1992-02-18 |
Sai P. Sunkara |
Nucleosides and their use as antineoplastic agents
|
US4681873A
(en)
*
|
1985-07-29 |
1987-07-21 |
Warner-Lambert Company |
4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
|
US4814438A
(en)
*
|
1986-12-24 |
1989-03-21 |
Eli Lilly And Company |
Immunoglobulin conjugates of 2',2'-difluronucleosides
|
US4994558A
(en)
*
|
1986-12-24 |
1991-02-19 |
Eli Lilly And Company |
Immunoglobulin conjugates
|
PT86377B
(pt)
*
|
1986-12-24 |
1990-11-20 |
Lilly Co Eli |
Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
|
EP0277599A3
(en)
*
|
1987-01-30 |
1990-05-09 |
Asahi Glass Company Ltd. |
Fluorine containing cyclopentane derivatives and processes for their production
|
CA1340645C
(en)
*
|
1987-04-17 |
1999-07-13 |
Victor E. Marquez |
Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
|
US5223608A
(en)
*
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
IL87517A
(en)
*
|
1987-08-28 |
1993-05-13 |
Lilly Co Eli |
Process for preparing an enantiomeric mixture of erythro and threo lactones
|
US4965374A
(en)
*
|
1987-08-28 |
1990-10-23 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4914028A
(en)
*
|
1988-02-10 |
1990-04-03 |
Eli Lilly And Company |
Method of preparing beta-2',2'-difluoronucleosides
|
ES2075040T3
(es)
*
|
1988-02-16 |
1995-10-01 |
Lilly Co Eli |
2',3'-dideoxi-2',2'-difluoronucleosidos.
|
US4983724A
(en)
*
|
1988-02-16 |
1991-01-08 |
Eli Lilly And Company |
Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
|
US5644043A
(en)
*
|
1988-02-16 |
1997-07-01 |
Eli Lilly And Company |
2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
|
ATE128141T1
(de)
*
|
1988-03-16 |
1995-10-15 |
Scripps Research Inst |
Als therapeutische mittel verwendbare substituierte adeninderivate.
|
US5057301A
(en)
*
|
1988-04-06 |
1991-10-15 |
Neorx Corporation |
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
|
JPH0232093A
(ja)
*
|
1988-06-08 |
1990-02-01 |
Merrell Dow Pharmaceut Inc |
抗レトロウィルスジフルオロ化ヌクレオシド類
|
US4987224A
(en)
*
|
1988-08-02 |
1991-01-22 |
University Of Georgia Research Foundation, Inc. |
Method of preparation of 2',3'-dideoxynucleosides
|
US5157114A
(en)
*
|
1988-08-19 |
1992-10-20 |
Burroughs Wellcome Co. |
2',3'-dideoxy-3'-fluoro-5-ethyngluridine
|
US4954623A
(en)
*
|
1989-03-20 |
1990-09-04 |
Eli Lilly And Company |
Recovery of difluoro sugar
|
CA2012129A1
(en)
*
|
1989-03-20 |
1990-09-20 |
Ramakrishnan Nagarajan |
Recovery of difluoro sugar
|
US5371210A
(en)
*
|
1992-06-22 |
1994-12-06 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5252756A
(en)
*
|
1992-06-22 |
1993-10-12 |
Eli Lilly And Company |
Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
|
US5426183A
(en)
*
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5594124A
(en)
*
|
1992-06-22 |
1997-01-14 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
|
US5256798A
(en)
*
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
YU43193A
(sh)
*
|
1992-06-22 |
1997-01-08 |
Eli Lilly And Company |
2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
|
MX9303713A
(es)
*
|
1992-06-22 |
1994-05-31 |
Lilly Co Eli |
Proceso estereoselectivo para preparar un derivadoribofuranosilo enriquecido con alfa anomero.
|
US5401861A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5401838A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
CZ123493A3
(en)
*
|
1992-06-22 |
1994-02-16 |
Lilly Co Eli |
Stereoselective anionic glycosylation process
|
US5606048A
(en)
*
|
1992-06-22 |
1997-02-25 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5821357A
(en)
*
|
1992-06-22 |
1998-10-13 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
|
US5256797A
(en)
*
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US5480992A
(en)
*
|
1993-09-16 |
1996-01-02 |
Eli Lilly And Company |
Anomeric fluororibosyl amines
|
US5428176A
(en)
*
|
1994-04-14 |
1995-06-27 |
Eli Lilly And Company |
Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
|
US5637688A
(en)
*
|
1994-12-13 |
1997-06-10 |
Eli Lilly And Company |
Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
|
US5521294A
(en)
*
|
1995-01-18 |
1996-05-28 |
Eli Lilly And Company |
2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
|
US5559222A
(en)
*
|
1995-02-03 |
1996-09-24 |
Eli Lilly And Company |
Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
|
CA2171518A1
(en)
*
|
1995-03-24 |
1996-09-25 |
Douglas Patton Kjell |
Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
|
US5633367A
(en)
|
1995-03-24 |
1997-05-27 |
Eli Lilly And Company |
Process for the preparation of a 2-substituted 3,3-difluorofuran
|
US6001994A
(en)
*
|
1995-12-13 |
1999-12-14 |
Eli Lilly And Company |
Process for making gemcitabine hydrochloride
|
EP0779275A2
(en)
|
1995-12-13 |
1997-06-18 |
Eli Lilly And Company |
Alpha, Alpha - Difluoro-beta -hydroxy thiol esters and their synthesis
|
US5756775A
(en)
*
|
1995-12-13 |
1998-05-26 |
Eli Lilly And Company |
Process to make α,α-difluoro-β-hydroxyl thiol esters
|
US5808020A
(en)
*
|
1996-08-12 |
1998-09-15 |
Associated Universities, Inc. |
Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
|
US6013790A
(en)
*
|
1996-09-25 |
2000-01-11 |
Board Of Regents University Of Nebraska-Lincoln |
Heavily fluorinated sugar analogs
|
AU6473098A
(en)
*
|
1997-03-24 |
1998-10-20 |
Eli Lilly And Company |
Difluoronucleoside phosphonic acids and derivatives thereof
|
EA200700564A1
(ru)
|
1998-02-25 |
2007-08-31 |
Эмори Юниверсити |
2`-фторнуклеозиды
|
TW466112B
(en)
*
|
1998-04-14 |
2001-12-01 |
Lilly Co Eli |
Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
|
US6326507B1
(en)
*
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
ES2318649T3
(es)
*
|
2000-10-20 |
2009-05-01 |
EISAI R&D MANAGEMENT CO., LTD. |
Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
|
US7435755B2
(en)
*
|
2000-11-28 |
2008-10-14 |
The Trustees Of Dartmouth College |
CDDO-compounds and combination therapies thereof
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
AU2002365256A1
(en)
*
|
2001-10-25 |
2003-07-30 |
Eli Lilly And Company |
Gemcitabine in the treatment of smallpox
|
CA2472581C
(en)
*
|
2002-01-15 |
2012-06-26 |
Trustees Of Dartmouth College |
Tricyclic-bis-enone derivatives and methods of use thereof
|
NZ534811A
(en)
*
|
2002-02-14 |
2007-07-27 |
Pharmasset Inc |
Modified fluorinated nucleoside analogues
|
JPWO2004080462A1
(ja)
*
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
AU2003239510A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
|
CA2525973A1
(en)
*
|
2003-05-20 |
2004-12-09 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
RU2358979C2
(ru)
|
2003-05-30 |
2009-06-20 |
Фармассет, Инк. |
Модифицированные фторированные аналоги нуклеозида
|
US20060034943A1
(en)
*
|
2003-10-31 |
2006-02-16 |
Technology Innovations Llc |
Process for treating a biological organism
|
JP4303726B2
(ja)
*
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
AU2005213372B2
(en)
*
|
2004-02-06 |
2011-03-24 |
Threshold Pharmaceuticals, Inc. |
Anti-cancer therapies
|
EP1732947B1
(en)
*
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
US20050249667A1
(en)
*
|
2004-03-24 |
2005-11-10 |
Tuszynski Jack A |
Process for treating a biological organism
|
PT1773856E
(pt)
*
|
2004-07-21 |
2012-05-14 |
Gilead Pharmasset Llc |
Preparação de 2-desoxi-2-fluoro-d-ribofuranosilo pirimidinas e purinas substituídas com alquilo e seus derivados
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
KR100578616B1
(ko)
*
|
2004-07-23 |
2006-05-10 |
한미약품 주식회사 |
D-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
|
WO2006011713A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Hanmi Pharm. Co., Ltd. |
1-α-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
|
CN101076536A
(zh)
*
|
2004-07-30 |
2007-11-21 |
药华医药股份有限公司 |
β-核苷的立体选择性合成
|
KR101177590B1
(ko)
|
2004-09-14 |
2012-08-27 |
파마셋 인코포레이티드 |
2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US20060089328A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solutions
|
US7563570B2
(en)
*
|
2004-10-29 |
2009-07-21 |
Pangaea Biotech |
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
|
JP2007522151A
(ja)
*
|
2004-12-08 |
2007-08-09 |
シコール インコーポレイティド |
ジフルオロヌクレオシド及びその調製方法
|
BRPI0519117A2
(pt)
*
|
2004-12-17 |
2008-12-23 |
Lilly Co Eli |
composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto
|
BRPI0606480A
(pt)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
EP1853616B1
(en)
*
|
2005-03-04 |
2010-02-24 |
Fresenius Kabi Oncology Limited |
Intermediate and process for preparing of beta-anomer enriched 2'-deoxy,2',2'-difluoro-d-ribofuranosyl nucleosides
|
US7485716B2
(en)
*
|
2005-05-02 |
2009-02-03 |
Pharmaessentia Corp. |
Stereoselective synthesis of β-nucleosides
|
AU2011202539B2
(en)
*
|
2005-06-03 |
2012-07-05 |
Scinopharm Taiwan, Ltd. |
Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
|
CN101203525B
(zh)
*
|
2005-06-03 |
2012-06-13 |
台湾神隆股份有限公司 |
制备α-端基异构体富集的2-脱氧-2,2-二氟-D-呋喃核糖基磺酸酯的方法及其制备β核苷的应用
|
ZA200800907B
(en)
|
2005-07-18 |
2010-04-28 |
Bipar Sciences Inc |
Treatment of cancer
|
AT502221A1
(de)
*
|
2005-07-20 |
2007-02-15 |
Pharmacon Forschung & Beratung Gmbh |
Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
|
EP1925941B1
(en)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
WO2007015257A2
(en)
*
|
2005-08-04 |
2007-02-08 |
Hetero Drugs Limited |
A process for the preparation of gemcitabine using novel intermediates
|
KR100990590B1
(ko)
*
|
2005-09-01 |
2010-10-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
붕해성이 개선된 의약 조성물의 제조 방법
|
JP2009513623A
(ja)
|
2005-10-28 |
2009-04-02 |
アーチ ファーマラブズ リミテッド |
塩酸ジェムシタビンの改良された製造方法
|
KR101353763B1
(ko)
*
|
2005-11-07 |
2014-01-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
US20090281301A1
(en)
*
|
2005-12-14 |
2009-11-12 |
Dong-A-Pharm.Co Ltd |
Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate
|
EP1994042A4
(en)
*
|
2006-02-06 |
2009-03-18 |
Reddys Lab Ltd Dr |
PREPARATION OF GEMCITABINE
|
CA2641719A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
US20070249823A1
(en)
*
|
2006-04-20 |
2007-10-25 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
CN104706637A
(zh)
*
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
US20090203693A1
(en)
*
|
2006-06-29 |
2009-08-13 |
Eisai R & D Management Co., Ltd. |
Therapeutic agent for liver fibrosis
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
KR100741310B1
(ko)
*
|
2006-08-01 |
2007-08-01 |
(주) 유일팜테크 |
젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
|
EP2065372B1
(en)
*
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
US20080161324A1
(en)
*
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
US8921340B2
(en)
|
2006-11-17 |
2014-12-30 |
Trustees Of Dartmouth College |
Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
|
JP2010510243A
(ja)
*
|
2006-11-17 |
2010-04-02 |
トラスティーズ オブ ダートマス カレッジ |
三環系−ビス−エノン(tbe)の合成および生物学的活性
|
US8299046B2
(en)
*
|
2006-11-17 |
2012-10-30 |
Trustees Of Dartmouth College |
Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
|
CA2675736A1
(en)
|
2007-01-19 |
2008-07-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
WO2008093855A1
(ja)
*
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
US7994310B2
(en)
*
|
2007-03-23 |
2011-08-09 |
Dongwoo Syntech Co., Ltd. |
Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
|
CN101024667B
(zh)
*
|
2007-03-30 |
2011-01-26 |
湖北益泰药业有限公司 |
盐酸吉西他宾的合成方法
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US8765690B2
(en)
*
|
2007-04-05 |
2014-07-01 |
Threshold Pharmaceuticals, Inc. |
Treatment of cancer with glufosfamide in patients not receiving insulin therapy
|
US20080262215A1
(en)
*
|
2007-04-23 |
2008-10-23 |
Chemagis Ltd. |
Gemcitabine production process
|
CN100475832C
(zh)
*
|
2007-05-31 |
2009-04-08 |
南京卡文迪许生物工程技术有限公司 |
一种新颖的高立体选择性合成吉西他滨工艺及中间体
|
US20090162288A1
(en)
*
|
2007-07-18 |
2009-06-25 |
Nanhai Chen |
Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
|
US20090048205A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Colin Meyer |
Combination therapy with synthetic triterpenoids and gemcitabine
|
TWI436775B
(zh)
*
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
US20090069354A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched gemcitabine
|
US8741858B2
(en)
|
2007-09-21 |
2014-06-03 |
Zhongxu Ren |
Oligomer-nucleoside phosphate conjugates
|
JP4253357B1
(ja)
|
2007-09-27 |
2009-04-08 |
株式会社湯山製作所 |
手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
|
JO2778B1
(en)
*
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
AU2008323923A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Pharmaessentia Corporation |
Novel synthesis of beta-nucleosides
|
BRPI0820298A8
(pt)
|
2007-11-09 |
2018-05-08 |
Affitech Res As |
composições e métodos de anticorpos anti-vegf
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
MX2010005221A
(es)
*
|
2007-11-12 |
2010-09-28 |
Bipar Sciences Inc |
Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
|
PL2252283T3
(pl)
|
2008-01-11 |
2019-09-30 |
Reata Pharmaceuticals, Inc. |
Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
|
BRPI0906576A2
(pt)
*
|
2008-01-29 |
2015-07-07 |
Eisai R&D Man Co Ltd |
Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
|
KR101665042B1
(ko)
|
2008-04-18 |
2016-10-11 |
리타 파마슈티컬스 잉크. |
소염성 골격군을 포함하는 화합물 및 사용 방법
|
US7915402B2
(en)
|
2008-04-18 |
2011-03-29 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
|
LT2271658T
(lt)
*
|
2008-04-18 |
2017-02-27 |
Reata Pharmaceuticals, Inc. |
Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai
|
WO2009146216A2
(en)
*
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
CN102083442B
(zh)
|
2008-04-18 |
2014-08-13 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
CN102216314A
(zh)
*
|
2008-06-12 |
2011-10-12 |
台湾神隆股份有限公司 |
吉西他滨碱的结晶多晶型物
|
EP2309860B1
(en)
*
|
2008-07-22 |
2014-01-08 |
Trustees of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
WO2010019396A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Threshold Pharmaceuticals, Inc. |
Administration of glufosfamide for the treatment of cancer
|
WO2010049947A2
(en)
*
|
2008-10-28 |
2010-05-06 |
Accrete Pharmaceutical Private Limited |
Preparation of gemcitabine and intermediates thereof
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
PA8855601A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
UY32546A
(es)
*
|
2009-04-06 |
2010-10-29 |
Eisai Inc |
Composiciones y metodos para tratar cancer
|
TWI477508B
(zh)
*
|
2009-04-06 |
2015-03-21 |
Otsuka Pharma Co Ltd |
用以治療癌症之組成物及方法
|
US8609631B2
(en)
|
2009-04-06 |
2013-12-17 |
Eisai Inc. |
Compositions and methods for treating cancer
|
JP5684787B2
(ja)
*
|
2009-04-06 |
2015-03-18 |
大塚製薬株式会社 |
シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
|
US20100273730A1
(en)
*
|
2009-04-27 |
2010-10-28 |
Innopharmax, Inc. |
Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2011016049A2
(en)
|
2009-07-31 |
2011-02-10 |
Astron Research Limited |
A stable composition of ready-to-use gemcitabine injection
|
US8993535B2
(en)
|
2009-09-04 |
2015-03-31 |
Merck Sharp & Dohme Corp. |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
US20130065883A1
(en)
|
2010-02-18 |
2013-03-14 |
Centro Nacional de Investigaceiones Oncologicas (CNIO) |
Triazolo [4, 5- B] Pyridin Derivatives
|
DK2547359T3
(en)
|
2010-03-15 |
2016-06-06 |
The Board Of Trustees Of The Univ Of Illionis |
Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
CA2794671C
(en)
|
2010-03-31 |
2018-05-01 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
WO2011143590A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
|
WO2011143593A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
|
JP5898074B2
(ja)
|
2010-06-25 |
2016-04-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
|
AU2011305655B2
(en)
|
2010-09-22 |
2015-11-05 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012069972A1
(en)
|
2010-11-19 |
2012-05-31 |
Piramal Life Sciences Limited |
A pharmaceutical combination for the treatment of breast cancer
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
CN102153602B
(zh)
*
|
2011-02-24 |
2013-11-06 |
中国农业大学 |
呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
|
CN102153601A
(zh)
*
|
2011-02-26 |
2011-08-17 |
湖南欧亚生物有限公司 |
一种高选择性的制备盐酸吉西他滨以及其中间体的方法
|
WO2012123889A1
(en)
|
2011-03-14 |
2012-09-20 |
Piramal Healthcare Limited |
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
RU2631240C2
(ru)
|
2011-04-01 |
2017-09-20 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
|
TWI462931B
(zh)
|
2011-04-07 |
2014-12-01 |
Pharmaessentia Corp |
β-核苷的合成技術
|
US9061041B2
(en)
|
2011-04-13 |
2015-06-23 |
Merck Sharp & Dohme Corp. |
2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
AU2012242978A1
(en)
|
2011-04-13 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
CN102453064B
(zh)
*
|
2011-06-30 |
2014-07-09 |
江苏豪森药业股份有限公司 |
制备吉西他滨盐酸盐的方法
|
US9408863B2
(en)
|
2011-07-13 |
2016-08-09 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
EP2731434A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
|
KR102090740B1
(ko)
|
2011-10-03 |
2020-03-18 |
엠엑스 아쥬바크 에이비 |
암 치료 및 식품 관련 화합물을 포함하는 의학 분야에서 양친매성 또는 소수성 분자를 위한 나노입자, 제조 방법 및 담체로의 용도
|
CN102417533A
(zh)
*
|
2011-10-28 |
2012-04-18 |
江苏正大清江制药有限公司 |
盐酸吉西他滨的合成方法
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
NO2755614T3
(es)
|
2012-01-03 |
2018-03-31 |
|
|
WO2013142124A1
(en)
|
2012-03-21 |
2013-09-26 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
CA3152081A1
(en)
|
2012-04-04 |
2013-10-10 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
|
US8921419B2
(en)
|
2012-05-08 |
2014-12-30 |
Trustees Of Dartmouth College |
Triterpenoids and compositions containing the same
|
SG11201407674TA
(en)
|
2012-05-22 |
2014-12-30 |
Idenix Pharmaceuticals Inc |
D-amino acid compounds for liver disease
|
CA2871359A1
(en)
|
2012-06-08 |
2013-12-12 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
EP2711008A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
|
EP2711007A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
|
EP2711009A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
|
TR201809048T4
(tr)
|
2012-10-08 |
2018-07-23 |
Centre Nat Rech Scient |
Hcv enfeksiyonu için 2'-kloro nükleosit analogları.
|
US9757432B2
(en)
|
2012-11-14 |
2017-09-12 |
Ohio State Innovation Foundation |
Materials and methods useful for treating glioblastorna
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
WO2014163558A1
(en)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
WO2014185540A1
(en)
|
2013-05-14 |
2014-11-20 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
JP6476591B2
(ja)
*
|
2013-06-05 |
2019-03-06 |
セントラル硝子株式会社 |
(2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類の製造方法
|
US20160324885A1
(en)
*
|
2013-07-10 |
2016-11-10 |
Asteriapharma Gmbh |
Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
|
CN105792845A
(zh)
*
|
2013-07-26 |
2016-07-20 |
施瑞修德制药公司 |
使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
|
EP4005560A1
(en)
|
2013-08-27 |
2022-06-01 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
KR102272773B1
(ko)
|
2013-10-29 |
2021-07-02 |
오츠카 세이야쿠 가부시키가이샤 |
2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
|
WO2015191563A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination chemotherapy comprising a liposomal prodrug of mitomycin c
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
IL13Rα2結合剤及び癌治療におけるその使用
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
CN107295800A
(zh)
*
|
2015-02-25 |
2017-10-24 |
配体药物公司 |
吉西他滨衍生物
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
RU2729936C2
(ru)
|
2015-06-16 |
2020-08-13 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противораковое средство
|
EP3344642A1
(en)
|
2015-09-02 |
2018-07-11 |
AbbVie Inc. |
Anti-viral tetrahydrofurane derivatives
|
JP7038653B2
(ja)
*
|
2015-10-05 |
2022-03-18 |
ニューカナ パブリック リミテッド カンパニー |
併用療法
|
ES2898890T3
(es)
|
2015-12-11 |
2022-03-09 |
NuCana plc |
Síntesis diastereoselectiva de derivados de fosfato y del profármaco de gemcitabina NUC-1031
|
IL261721B
(en)
|
2016-03-15 |
2022-07-01 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
WO2018035046A1
(en)
|
2016-08-15 |
2018-02-22 |
President And Fellows Of Harvard College |
Treating infections using idsd from proteus mirabilis
|
AU2017361541A1
(en)
|
2016-11-21 |
2019-07-11 |
Bexion Pharmaceuticals, Inc. |
A combination therapy including SapC-DOPS for the treatment of pancreatic cancer
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
CA3061621A1
(en)
|
2017-04-26 |
2018-11-01 |
Thomas I. Kalman |
Multitargeted nucleoside derivatives
|
TW201912173A
(zh)
|
2017-08-07 |
2019-04-01 |
美商安進公司 |
三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
|
EP3826667B1
(en)
|
2017-09-18 |
2024-04-17 |
The Regents of the University of California |
Claudin6 antibodies and methods of treating cancer
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
KR20200118827A
(ko)
|
2018-02-02 |
2020-10-16 |
마베릭스 온콜로지, 잉크. |
젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
|
WO2019178433A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
JP2022517352A
(ja)
|
2019-01-11 |
2022-03-08 |
リポメディックス・ファーマシューティカルズ・リミテッド |
マイトマイシンcのリポソーム化プロドラッグを含むリポソーム組成物および製造法
|
CN114206934A
(zh)
|
2019-03-20 |
2022-03-18 |
加利福尼亚大学董事会 |
密封蛋白-6双特异性抗体
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
CA3132656A1
(en)
|
2019-04-30 |
2020-11-05 |
Instituto De Medicina Molecular Joao Lobo Antunes |
Rank pathway inhibitors in combination with cdk inhibitors
|
AU2020303986A1
(en)
|
2019-06-24 |
2021-12-09 |
Amgen Inc. |
Inhibition of SIRP-gamma for cancer treatment
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
WO2021216427A1
(en)
|
2020-04-21 |
2021-10-28 |
Ligand Pharmaceuticals, Inc. |
Nucleotide prodrug compounds
|